Triazole Containing Novobiocin and Biphenyl Amides as Hsp90 C-Terminal Inhibitors

Area of Science:

• Oncology
• Medicinal Chemistry
• Molecular Biology

Background:

• Heat shock protein 90 (Hsp90) is a crucial molecular chaperone implicated in cancer progression.
• Hsp90 N-terminal inhibitors face challenges due to inducing prosurvival heat shock responses.
• Hsp90 C-terminal inhibitors offer a potential therapeutic advantage by dissociating client protein degradation from this detrimental response.

Purpose of the Study:

• To design and synthesize novel Hsp90 inhibitors targeting the C-terminus.
• To evaluate the antiproliferative activity of these new compounds against breast cancer cell lines.
• To confirm the Hsp90 inhibitory mechanism of action.

Main Methods:

• Structure-activity relationship (SAR) guided modification of coumarin and biphenyl scaffolds.
• Incorporation of a 1,2,3-triazole side chain.
• Antiproliferative assays using SKBr3 and MCF-7 breast cancer cell lines.
• Western blot analysis to assess Hsp90 client protein degradation and Hsp90 inhibition.

Main Results:

• The synthesized triazole-containing compounds exhibited improved antiproliferative activity against SKBr3 and MCF-7 cells compared to previous analogs.
• Western blot analysis confirmed that these compounds effectively inhibit Hsp90 activity.
• The study identified a new chemical scaffold for developing potent Hsp90 inhibitors.

Conclusions:

• The novel 1,2,3-triazole-containing Hsp90 C-terminal inhibitors demonstrate significant promise as anticancer agents.
• These compounds represent a viable alternative to N-terminal inhibitors, avoiding the prosurvival heat shock response.
• Further optimization of this scaffold could lead to the development of next-generation cancer chemotherapeutics.